Treatment Approach At Strong Health, arthritis-focused peptide therapy follows a careful, individualized clinical approach: Joint assessment: Physical examination, review of imaging (X-rays, MRI if available), and assessment of functional limitations and pain levels Medical history review: Current medications, prior treatments, comorbidities, and treatment goals Peptide selection: Physician determines the most appropriate peptide(s) based on the type and severity of arthritis, affected joints, and overall health Protocol design: Dosing, administration route (subcutaneous or localized injection), and treatment duration are individualized Complementary integration: Peptide therapy is integrated with other evidence-based approaches: physical therapy, appropriate exercise, weight management, and nutritional support Monitoring: Regular follow-ups to assess symptom improvement, functional outcomes, and any side effects Medication coordination: Close coordination with any existing arthritis medications to avoid interactions and optimize the overall treatment plan Peptides vs
FDA has also proposed that BPC-157 free base and BPC-157 acetate not be added to the 503A Bulks List at its July 23, 2026 Pharmacy Compounding Advisory Committee meeting
No reader of this blog post should act or refrain from acting on the basis of any information included in, or accessible through, this blog post without seeking the appropriate medical advice on the particular facts and circumstances at issue from a licensed medical professional in the recipients state, country or other appropriate licensing jurisdiction
In addition, Zealand and Roche are developing petrelintide as standalone treatment and in combinations, including a program with Roche's incretin candidate CT-388
Standard treatments remove or close off damaged veins
